SCHEMBL16058506

SCHEMBL16058506

Cc1cccc(-c2ccc(-c3ccn(C(=O)O)c(=O)c3C)cc2C)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP2 P08253 1/20 0.41
▸ MMP3 P08254 1/20 0.41
▸ CNR2 P34972 2/20 0.40
▸ AKR1C3 P42330 2/20 0.38
▸ AKR1C2 P52895 2/20 0.38
▸ PGR P06401 1/20 0.38
▸ LDHA P00338 1/20 0.37
▸ LDHB P07195 1/20 0.37
▸ NR3C2 P08235 1/20 0.37
▸ CNR1 P21554 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ CA12 O43570 1/20 0.35
▸ CA9 Q16790 1/20 0.35
▸ FFAR1 O14842 1/20 0.35
▸ KMT2A Q03164 1/20 0.34
▸ PARP10 Q53GL7 1/20 0.34
▸ PARP11 Q9NR21 1/20 0.34
▸ TACR1 P25103 1/20 0.34
▸ OPRD1 P41143 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16056962 0.91 ESR2 (0.43) MMP2MMP3AKR1C3AKR1C2SMN1; SMN2
SCHEMBL16058477 0.88 PGR (0.43) CNR2AKR1C2PGRTSHRSMN1; SMN2
SCHEMBL16056873 0.85 MCL1 (0.42) LDHAFFAR1
SCHEMBL14975255 0.81 COMT (0.42) POLB
SCHEMBL14975270 0.80 KDM4E (0.39) SMN1; SMN2KMT2APARP10PARP11MAPT
SCHEMBL16057665 0.76 PLA2G2A (0.43) FFAR1
SCHEMBL16057190 0.72 LDHA (0.43) LDHASMN1; SMN2FFAR1
SCHEMBL16058367 0.71 DHODH (0.43) MAPT
SCHEMBL16057641 0.71 MKNK1 (0.48) PARP10PARP11
SCHEMBL14976923 0.71 ALDH1A1 (0.43) AKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9828338-B2 Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-11-28 — — US disclosed
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-03-10 — — US disclosed
WO-2014144836-A2 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS NAAA, FAAH, FAAH2 MMP2 1442/4885MMP3 1419/4885CNR2 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback